Get started
Author

Per Edlund

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
2018 · Annemieke Cats, Edwin P M Jansen, et al. · The Lancet Oncology · 572
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
2014 · X. Pivot, J. Gligorov, et al. · Annals of Oncology · 182
Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
2008 · Bent Kristensen, Bent Ejlertsen, et al. · Acta Oncologica · 70
PDF
Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
2007 · Bent Ejlertsen, Henning T. Mouridsen, et al. · European Journal of Cancer · 63
Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer
2006 · Bent Ejlertsen, Henning T. Mouridsen, et al. · Journal of Clinical Oncology · 52
Breast cancer on the Internet: the quality of Swedish breast cancer websites
2004 · Elisabeth Nilsson-Ihrfelt, Marie-Louise Fjällskog, et al. · The Breast · 44
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
2024 · Nicholas Turner, Cristina Saura, et al. · Journal of Clinical Oncology · 40
PDF
Inter-observer variation in delineating the coronary arteries as organs at risk
2016 · Anna-Karin Wennstig, Hans Garmo, et al. · Radiotherapy and Oncology · 32
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
2015 · Carl Blomberg, Jonas Nilsson, et al. · PubMed · 23
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
2010 · Sara Margolin, Nils-Olof Bengtsson, et al. · Acta Oncologica · 19
PDF
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
2024 · Alexios Matikas, Volker Möbus, et al. · Journal of Clinical Oncology · 15
PDF
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
2011 · Per Edlund, Johan Ahlgren, et al. · Acta Oncologica · 10
PDF
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
2017 · Alexios Matikas, Sara Margolin, et al. · Breast Cancer Research and Treatment · 8
PDF
Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended Radiotherapy.
2015 · Georg Holgersson, Stefan Bergström, et al. · PubMed · 6
A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer.
2011 · H. Lindman, M. Andersson, et al. · Journal of Clinical Oncology · 5
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1
2020 · Paula Poikonen-Saksela, Henrik Lindman, et al. · Acta Oncologica · 4
PDF
Radiosensitizing Biological Modifiers Enhancing Efficacy in Non-Small-Cell Lung Cancer Treated with Radiotherapy
2013 · Georg Holgersson, Stefan Bergström, et al. · Lung Cancer Management · 1
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004–1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.
2017 · Alexios Matikas, Sara Margolin, et al. · Journal of Clinical Oncology
Abstract P1-10-05: Omitting radiotherapy in women ≥ 65 years with early breast cancer and favorable histopathology after breast-conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe
2017 · KKA Villman, Å Wickberg, et al. · Cancer Research
Works count: 20
Citation count: 1,146
H-index: 11
I10-index: 12
Year
Topic
Type